Lipoprotein(a): A Genetically Determined, Causal, and Prevalent

Pharmaceuticals, Free Full-Text

LPA disruption with AAV-CRISPR potently lowers plasma apo(a) in transgenic mouse model: A proof-of-concept study: Molecular Therapy - Methods & Clinical Development

RNA drugs lower lipoprotein(a) and genetically driven cholesterol

Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis - The Lancet Diabetes & Endocrinology

Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease - Professional Heart Daily

Lipoprotein(a): Pathophysiology, measurement, indication and treatment in cardiovascular disease. A consensus statement from the Nouvelle Société Francophone d'Athérosclérose (NSFA) - ScienceDirect

DNA Story: Lp(a) and Risk of Cardiovascular Disease - GB HealthWatch

Lipoprotein(a) in an adult sample from the Russian population: distribution and association with atherosclerotic cardiovascular diseases

Diseases, Free Full-Text

Genome-Wide Association Study and Identification of a Protective Missense Variant on Lipoprotein(a) Concentration

Plasminogen Receptors Promote Lipoprotein(a) Uptake by Enhancing Surface Binding and Facilitating Macropinocytosis

The relationship between lipoprotein(a) and risk of cardiovascular disease: a Mendelian randomization analysis, European Journal of Medical Research

Lipoprotein(a) and Atherosclerotic Cardiovascular Diseases: Evidence from Chinese Population

Genome-Wide Association Study Highlights APOH as a Novel Locus for Lipoprotein(a) Levels—Brief Report

Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease